Ten years of clinical trial registration in a resource-limited setting: Experience of the Sri Lanka clinical trials registry

2018 ◽  
Vol 11 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Udaya K. Ranawaka ◽  
Ashwini de Abrew ◽  
Manu Wimalachandra ◽  
Nithushi Samaranayake ◽  
Colvin Goonaratna
2020 ◽  
Author(s):  
Fei Zhao ◽  
Wei Xue ◽  
Wenyuan Qi ◽  
Duanduan Cong ◽  
Huiqing Yao ◽  
...  

BACKGROUND Background: World health organization and the international committee of medical journal editors call for clinical trial registration before the start of the recruitment of participants. The registration promotes transparency and accessibility to all researchers and targeted patients globally. OBJECTIVE Objective: We conducted this research to explore the tendency and change of clinical trial registration among different classifications, in order to show the development of the registered clinical trials in the world. METHODS Methods: All clinical trials which had registered in the database of the International Clinical Trials Registry Platform (ICTRP) from 2005 to 2019 were collected as the database for analysis in this study. Developments of clinical trial registration were analyzed in terms of different registries, different regions, different income country classifications by covariance analysis for the difference in clinical trial registration and Cochran-Armitage Test for trend. The sample size enrolled was analyzed to explore whether there was any change in the scale of the clinical trials over time. RESULTS Results: Totally 205,228 clinical trials were registered in the ICTRP from 2005 to 2019. The numbers of clinical trial implementation annually increased as an exponential function (R2=0.83,t=10.45,P< .001). Almost 65% of clinical trials were performed in North American and East Asia & Pacific regions. There was a significant increasing trend in the numbers of clinical trial performance over time (F=184.85, P< .001). The numbers of clinical trial registration were different significantly between different income classifications of the country (F=90.84, P< .001). The sample sizes of the same Phases of clinical trials had no significant difference adjusted by income classification over time changes (F=0.57, P= .45). CONCLUSIONS Conclusions: The clinical trials were becoming flourishing in the world. Most of the clinical trials had performed in high and upper-middle-income countries, especially North American and East Asia & Pacific. And the lower-middle-income countries had a much faster-increasing trend in the clinical trial performance.


2015 ◽  
Vol 134 (1) ◽  
pp. 28-33 ◽  
Author(s):  
Carolina Gomes Freitas ◽  
Thomas Fernando Coelho Pesavento ◽  
Maurício Reis Pedrosa ◽  
Rachel Riera ◽  
Maria Regina Torloni

CONTEXT AND OBJECTIVE: Clinical trial registration is a prerequisite for publication in respected scientific journals. Recent Brazilian regulations also require registration of some clinical trials in the Brazilian Clinical Trials Registry (ReBEC) but there is little information available about practical issues involved in the registration process. This article discusses the importance of clinical trial registration and the practical issues involved in this process. DESIGN AND SETTING: Descriptive study conducted by researchers within a postgraduate program at a public university in São Paulo, Brazil. METHODS: Information was obtained from clinical trial registry platforms, article reference lists and websites (last search: September 2014) on the following topics: definition of a clinical trial, history, purpose and importance of registry platforms, the information that should be registered and the registration process. RESULTS: Clinical trial registration aims to avoid publication bias and is required by Brazilian journals indexed in LILACS and SciELO and by journals affiliated to the International Committee of Medical Journal Editors (ICMJE). Recent Brazilian regulations require that all clinical trials (phases I to IV) involving new drugs to be marketed in this country must be registered in ReBEC. The pros and cons of using different clinical trial registration platforms are discussed. CONCLUSIONS: Clinical trial registration is important and various mechanisms to enforce its implementation now exist. Researchers should take into account national regulations and publication requirements when choosing the platform on which they will register their trial.


2013 ◽  
Vol 29 (6) ◽  
pp. 1095-1100 ◽  
Author(s):  
Ludovic Reveiz ◽  
Eleana Villanueva ◽  
Chimaraoke Iko ◽  
Iveta Simera

The objective of this study was to determine to what extent Latin American and Caribbean biomedical journals have endorsed and complied with clinical trial registration and reporting guidelines. A search of randomized clinical trials was carried out using the LILACS database. The randomized clinical trials identified through the search were assessed to determine whether trial registration and CONSORT guidance was mentioned. Information regarding endorsement of the ICMJE, trial registration and other reporting guidelines was extracted from the online instructions for authors of the journals included in the study. The search identified 477 references. We assessed a random sample of 240 titles of which 101 were randomized clinical trials published in 56 journals. Trial registration was reported in 19.8% of the randomized clinical trials, 6.9% were prospectively registered and 3% mentioned CONSORT. The ICMJE was mentioned by 68% of the journals and 36% of journals required trial registration. Fewer journals provided advice on reporting guidelines: CONSORT (13%), PRISMA (1.8%), STROBE (1.8%), and the EQUATOR network (3.6%). Wider endorsement of trial registration and adherence to reporting guidelines is necessary in clinical trials conducted in Latin America and the Caribbean.


BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e025218 ◽  
Author(s):  
Xuan Zhang ◽  
Ran Tian ◽  
Zhen Yang ◽  
Chen Zhao ◽  
Liang Yao ◽  
...  

ObjectiveThis study aimed to assess the registration quality of clinical trials (CTs) with traditional Chinese medicine (TCM) in the WHO International Clinical Trials Registry Platform (ICTRP) and identify the common problems if any.MethodsThe ICTRP database was searched for all TCM CTs that were registered up to 31 December 2017. Registered information of each trial was collected from specific registry involved in ICTRP through hyperlink. The primary analysis was to assess the reporting quality of registered trials with TCM interventions, which is based on the minimum 20 items of WHO Trial Registration Data Set (TRDS, V.1.2.1) plus optional additional three items recommended by ICTRP, and some specific items for TCM information (including TCM intervention, diagnosis, outcome and rationale). Descriptive statistics were additionally used to analyse the baseline characteristics of TCM trial registrations.ResultsA total of 3339 records in 15 registries were examined. The number of TCM registered trials has increased rapidly after the requirement of mandatory trial registration proposed by International Committee of Medical Journal Editors on 1 July 2005, and the top two registries were Chinese Clinical Trial Registry and ClincialTrials.gov. Of 3339 trials, 61% were prospective registration and 12.8% shared resultant publications. There were 2955 interventional trials but none of them had a 100% reporting rate of the minimum 20 items and additional three items. The reporting quality of these 23 items was not optimal due to 11 of them had a lower reporting rate (<65%). For TCM details, 49.2% lacked information on description of TCM intervention(s), 85.9% did not contain TCM diagnosis criteria, 92.6% did not use TCM outcome(s) and 67.1% lacked information on TCM background and rationale.ConclusionThe registration quality of TCM CTs should be improved by prospective registration, full completion of WHO TRDS, full reporting of TCM information and results sharing. Further full set of trial registration items for TCM trials should be developed thus to standardise the content of TCM trial registration.


2018 ◽  
Vol 38 (5) ◽  
pp. 343-348 ◽  
Author(s):  
Robert Rope ◽  
Nishantha Nanayakkara ◽  
Abdul Wazil ◽  
Sewmini Dickowita ◽  
Rajitha Abeyeskera ◽  
...  

BackgroundDespite growing need, treatment for end-stage renal disease is limited in low- and middle-income countries due to resource restraints. We describe the development of an educational curriculum and quality improvement program to support continuous ambulatory peritoneal dialysis (CAPD) performed primarily by non-nephrology providers in Sri Lanka.MethodsWe developed a program of education, outcome tracking, and expert consultation to support providers in Kandy, Sri Lanka. Education included videos and in-person didactics covering core topics in CAPD. Event-tracking sheets recorded root causes and management of infections and hospitalizations. Conferences reviewed clinical cases and overall clinic management. We evaluated the patient census, peritonitis rates, and root causes and management of infections over 1 year.ResultsThe curriculum was published through the International Society of Nephrology online academy. High provider turnover limited curriculum assessments. The CAPD patient census rose from 63 to 116 during the year. The peritonitis rate declined significantly, from 0.8 episodes per patient-year in the first 6 months to 0.4 in the latter 6 months, though the most common root causes of peritonitis, related to contamination events and hygiene, persisted. The appropriate ascertainment of culture data and prescription of antibiotics also increased.ConclusionsOur project supported the expansion of a CAPD program in a resource-limited setting, while also improving peritonitis outcomes. Ongoing challenges include ensuring a durable educational system for rotating providers, tracking outcomes beyond peritonitis, and formalizing management protocols. Our program can serve as an example of how established dialysis programs can support the burgeoning work of providers in resource-limited setting.


2012 ◽  
Vol 94 (10S) ◽  
pp. 1090
Author(s):  
N. Gunawansa ◽  
M. Wijeyaratne ◽  
R. Cassim ◽  
R. Ubeysiri ◽  
R. Dissanayake ◽  
...  

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e019983 ◽  
Author(s):  
Kylie Elizabeth Hunter ◽  
Anna Lene Seidler ◽  
Lisa M Askie

ObjectivesTo analyse prospective versus retrospective trial registration trends on the Australian New Zealand Clinical Trials Registry (ANZCTR) and to evaluate the reasons for non-compliance with prospective registration.DesignPart 1: Descriptive analysis of trial registration trends from 2006 to 2015. Part 2: Online registrant survey.ParticipantsPart 1: All interventional trials registered on ANZCTR from 2006 to 2015. Part 2: Random sample of those who had retrospectively registered a trial on ANZCTR between 2010 and 2015.Main outcome measuresPart 1: Proportion of prospective versus retrospective clinical trial registrations (ie, registration before versus after enrolment of the first participant) on the ANZCTR overall and by various key metrics, such as sponsor, funder, recruitment country and sample size. Part 2: Reasons for non-compliance with prospective registration and perceived usefulness of various proposed mechanisms to improve prospective registration compliance.ResultsPart 1: Analysis of the complete dataset of 9450 trials revealed that compliance with prospective registration increased from 48% (216 out of 446 trials) in 2006 to 63% (723/1148) in 2012 and has since plateaued at around 64%. Patterns of compliance were relatively consistent across sponsor and funder types (industry vs non-industry), type of intervention (drug vs non-drug) and size of trial (n<100, 100–500, >500). However, primary sponsors from Australia/New Zealand were almost twice as likely to register prospectively (62%; 4613/7452) compared with sponsors from other countries with a WHO Network Registry (35%; 377/1084) or sponsors from countries without a WHO Registry (29%; 230/781). Part 2: The majority (56%; 84/149) of survey respondents cited lack of awareness as a reason for not registering their study prospectively. Seventy-four per cent (111/149) stated that linking registration to ethics approval would facilitate prospective registration.ConclusionsDespite some progress, compliance with prospective registration remains suboptimal. Linking registration to ethics approval was the favoured strategy among those sampled for improving compliance.


2020 ◽  
Author(s):  
Xiaoqiong Cai ◽  
Zengliang Zheng ◽  
Jihan Huang ◽  
Qianmin Su

Abstract Background As a highly contagious disease, COVID-19 is raging on and is faced by every human being. Clinical trials are one of the most important means of investigating treatments for COVID-19, and their effective implementations may address the massive spread of the pandemic. As clinical trials continue to be conducted, the inability to view large amounts of data at a glance becomes a problem for many researchers. In order to provide reference and assistance for clinical trial design, this study collected and analyzed the current COVID-19 clinical trial registration data from multiple sources, and subsequently discussed their research status and developmental trend. Method The registered data of COVID-19 clinical trials were gathered from the ChiCTR and ClinicalTrials.gov website, which were transformed by Python and further demonstrated by Apache ECharts. Results As of March 28, 2020, records of 677 eligible registered trials had been retrieved. Overall, there are 407 (60.12%) interventional studies and 270 (39.12%) observational studies; 522 (77.10%) trials were conducted by hospitals; 53.32% of trials would be completed within six months; 523 (77.25%) subjects in trials were confirmed cases. Among interventional studies, 70.27% of the trials were randomized parallel studies; 55 (13.51%) trials considered time condition for clinical recovery as the primary endpoint, and 46 (11.30%) trials through clinical parameters and laboratory index as the primary endpoint. In the selection of intervention measures, chemical or biological agents constituted 43.49%, of which antiviral ones accounted for 14.50%, and antimalarials accounted for 8.85%, and 98 (24.14%) cases of studies involving TCM or integrated medicine. In addition, this study further analyzed antiviral drugs and explored possibilities of using combined drugs. Although a large number of clinical trials are already underway, interim research data will be helpful for future trial design and drug selection. Conclusions By compiling representative information of topical COVID-19 clinical trial registration, this study complements and enhances the effects of future researchers' trial designs.


Sign in / Sign up

Export Citation Format

Share Document